2D and 3D QSAR Analysis of Imidazole Derivatives as Heme Oxygenase Inhibitor

  • Darshana Gohate Department of Pharmacy, Barkatullah University, Bhopal (M.P), India - 462026
  • Parul Mehta School of Pharmacy, LNCT University, Kolar, Bhopal


Selective inhibition of heme oxygenase is an important strategy in design of potent inhibitors of enzyme for the treatment of neonatal jaundice, cancer and many more. QSAR analysis is employed for a given set of compounds containing imidazole pharmacophore in order to establish a relationship between the biological activity and related descriptors, which provides us an idea to gain a potent inhibitor with lesser side effects. In this paper we present results of 2D and 3D QSAR studies of series of 26 molecules containing imidazole pharmacophore as selective heme oxygenase inhibitor using V Life MDS 3.5 Software. The 2D QSAR studies was performed using Partial Least Square Regression method and the 3D QSAR studies was performed using k- Nearest Neighbor Molecular Field Analysis(kNN- MFA) method. The analysis has produced good predictive and statistically significant QSAR models. 2D QSAR studies produced good statistical model with r2 value 0.8487, cross validated r2 value 0.6553 and prd_r2 value 0.7478 by PLSR method while 3D QSAR model gave statistical value of cross validated r2 value 0.5493 and pred_r2 value 0.3358. The results of the QSAR analysis suggested that the 2-D descriptor viz. physicochemical and alignment independent played an important role for heme oxygenase inhibition and the 3-D descriptors electrostatic and steric revealed the relative positions and range for substitution in a molecule. In 3D model, grid suggested that a positive electrostatic potential is favorable for increase in biological activity and the steric field with negative range and the negative range indicates that negative steric potential is favorable for increase in the activity. Thus, the descriptors generated by 2-D and 3-D QSAR analysis were useful in designing of potent molecules.

Keywords: Heme Oxygenase Inhibitor, HO-1, 2D QSAR, 3D QSAR, kNN-MFA


1. Alam J, Igarashi K, Immenschuh S, Shibahara S,Tyrrell RM. Regulation of heme oxygenase-1 gene transcription: Recent advances and highlights from the International conference. Antioxid. & Red. Signal. 2004; 6: 924-933.
2. Roman G, Riley JG, Vlahakis JZ, Kinobe RT, Brien JF, Nakatsu K, Szarek WA. Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: Effect of halogen substitution in the phenyl ring. Bioorg. & Med. Chem. 2007; 15: 3225–3234.
3. Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, Szarek WA. Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors. Bioorg. & Med. Chem. Lett. 2005; 15:1457–1461.
4. Cashore WJ, Oh W. Unbound Bilirubin and Kernicterus in Low-Birth-Weight Infants. Pediatrics. 1982; 69: 481–485.
5. Bhutani VK, Performance evaluation for neonatal phototherapy. Ind. Pediatrics. 2009; 46: 19-21.
6. Cohen AN, Ostrow JD.New Concepts in Phototherapy: Photoisomerization of Bilirubin IXα and Potential Toxic Effects of Light, Pediatrics. 1980; 65:740–750.
7. Rosenstein BS, Ducore JM. Enhancement by bilirubin of DNA damage induced in human cells exposed to phototherapy light. Pediatric. Res. 1984; 18: 3–6.
8. Moseley MJ, Fielder AR.Phototherapy: an ocular hazard revisited. Arch. Dis. Child. 1988; 63: 886–887.
9. Chen M, Regan RF. Time course of increased heme oxygenase activity and expression after experimental intracerebral hemorrhage: correlation with oxidative injury. J. Neurochem. 2007; 103: 2015–2021.
10. Gong Y, Tian H, Xi G, Keep RF, Hoff JT, Hua Y. Systemic zinc protoporphyrin administration reduces intracerebral hemorrhage-induced brain injury. Acta. Neurochir. Suppl. 2006; 96: 232–236.
11. Wagner KR, Hua Y, Courten-Myers GM , Broderick JP, Nishimura RN, Lu SY, Dwyer BE. Tin-mesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: in vivo and in vitro studies. Cell Mol. Biol. 2000;46: 597–608.
12. Fang J, Sawa T,AkaikeT . In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003; 63: 3567-74.
13. Tanaka S, Akaike T, Fang J, Beppu T, Ogawa M, Tamura F, Miyamoto Y, Maeda H, Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour. Br. J. Cancer. 2003; 88: 902-09.
14. Fang J , Akaike T, Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis. 2004: 9: 27-35.
15. Vlahakis JZ, Kinobe RT, Bowers RJ, Brien JF, Nakatsu K, Szarek WA. Imidazole-Dioxolane Compounds as Isozyme-Selective Heme Oxygenase Inhibitors. J. Med. Chem. 2006; 49: 4437-4441.
16. Maines MD. The heme oxygenase system: A regulator of second messenger gases, Ann. Rev.of Pharmacol. & Toxicol. 1997;37: 517-554.
17. Kinobe RT, Vlahakis JZ, Vreman HJ, Stevenson DK, Brien JF, Szarek WA, Nakatsu K. Selectivity of imidazole–dioxolane compounds for in vitro inhibition of microsomal haem oxygenase isoforms. Brit. J. of Pharmacol. 2006; 147: 307–315.
18. DeNagel DC, Verity AN, Madden FE, Yang CO, Sangameswaran L, Johnson RM. Identification of non-porphyrin inhibitors of heme oxygenase-1. Society for Neurosci. 1998; 24: 2058.
19. Tuck SF, Patel H, Safi E, Robinson CH. Lanosterol 14 alpha-demethylase (P45014DM): effects of P45014DM inhibitors on sterol biosynthesis downstream of lanosterol. J. of Lip. Res. 1991; 32: 893.
20. Jain KS, Kathiravan MK, Somania RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg. & Med. Chem. 2007; 15:4674–4699.
21. Zhang F, Kaide JI, Rodriguez-Mulero F, Abraham NG, Nasjletti A. Vasoregulatory function of the heme-heme oxygenase-carbon monoxide system. Am. J. of Hyperten. 2001; 14: 62S-67S.
22. Mghazli S, Jaouad A, Mansour M, Villemin D, Cherqaoui D. Neural Networks Studies:quantitative structure-activity relationships of antifungal 1-[2-(substituted phenyl)allyl]imidazoles and related compounds. Chemosph. 2001; 43: 385-390.
23. Miranda PO, Gundersen LL. Synthesis of Imidazole Derivatives with Antimycobacterial Activity.Arch. Pharm. Chem. Life Sci. 2010; 343: 40-47.
24. Lean TH, Vengadasalam D. Treatment of vaginal trichomoniasis with a new anti-protozoal compound (-chloromethyl-2-methyl-5-nitro-1-imidazole-ethanol). Brit. J. of Veneral Diseases. 1973; 49: 69-71.
25. Palin R, Clark JK, Evans L, Houghton AK, Jones PS, Prosser A, Wishart G, Yoshiizumi K. Structure–activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties. Bioorg. & Med. Chem. 2008; 16: 2829–2851.
26. Wachall BG, Hector M, Zhuang Y, Hartmann RW. Imidazole substituted biphenyls: A new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer. Biorg. and Med. Chem. 1999; 7: 1913-1924.
27. Yoo SE, Kim SK, Lee SH, Yi KY, Lee DW, A comparative molecular field analysis and molecular modelling studies on pyridylimidazole type of angiotensin II antagonists. Bioorg. & Med. Chem. 1999;7: 2971- 2976.
28. Hadizadeh F, Hosseinzadeh H, Shariaty VSM, Seifi M, Kazemi S. Synthesis and Antidepressant Activity of N-Substituted Imidazole-5-Carboxamides in Forced Swimming Test Model. Iranian J. of Pharm. Res. 2008; 7: 29-33.
29. Mor M, Bordi F, Silva C, Rivara S, Zuliani V, Vacondio F, Rivara M, Barocelli E, Bertoni S, Ballabeni V, Magnanini F, Impiciatore M, Plazzi PV. Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. Biorg. and Med. Chem. 2004; 12: 663-674.
30. Clough DP, Hatton R, Pettinger SJ, Samuels GM, Shaw A. Substituted aryl-tetrahydro-pyrrolo imidazoles: a new class of centrally acting antihypertensives. Brit. J. Pharmacol. 1978; 62: 385P-386P.
31. Sugishima M, Higashimoto Y, Oishi T, Takahashi H, Sakamoto H, Noguchi M, Fukuyama K. X-ray Crystallographic and Biochemical Characterization of the Inhibitory Action of an Imidazole−Dioxolane Compound on Heme Oxygenase. Biochemistry. 2007; 46: 1860–1867.
32. Rahman MN, Vlahakis JZ, Szarek WA, Nakatsu K, Jia Z. X-ray crystal structure of human heme oxygenase-1 in complex with 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone: a common binding mode for imidazole-based heme oxygenase-1 inhibitors. J. Med. Chem. 2008; 51: 5943–5952.
33. Rahman MN, Vlahakis JZ, Vukomanovic D, Szarek WA, Nakatsu K, Jia Z. X-ray crystal structure of human heme oxygenase-1 with (2R, 4S)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-1-yl)methyl]-4[((5-trifluoromethylpyridin-2-yl)thio)methyl]-1,3-dioxolane: a novel inducible binding mode. J. Med. Chem. 2009; 52: 4946–4950.
34. Roman G, Rahman MN, Vukomanovic D, Jia Z, Nakatsu K, Szarek W. Heme oxygenase inhibition by 2-oxy-substituted 1-azolyl-4-phenylbutanes: effect of variation of the azole moiety. X-ray crystal structure of human heme oxygenase-1 in complex with 4-phenyl-1-(1H-1,2,4-triazol-1-yl)-2-butanone. Chem. Biol. Drug Des. 2010; 75: 68-90.
35. Rahman MN, Vlahakis JZ, Roman G, Vukomanovic D, Szarek WA, Nakatsu K, Jia Z. Structural characterization of human heme oxygenase-1 in complex with azole-based inhibitors. J. of Inorg. Biochem. 2010; 104: 324-330.
36. Vlahakis JZ, Humb M, Rahman MN , Jia Z, Nakatsu K , Szarek WA. Synthesis and evaluation of imidazole–dioxolane compounds as selective heme oxygenase inhibitors: effect of substituents at the 4-position of the dioxolane ring. Bioorg. & Med. Chem. 2009; 17: 2461–2475.
37. VLife MDS 3.5, Molecular Design Suite, VLife Sciences Technologies Pvt. Ltd., Pune, India, (www.vlifesciences.com)
38. Ajmani S, Jadhav K, Kulkarni SA. Three-Dimensional QSAR Using the k-Nearest Neighbor Method and Its Interpretation. J. Chem. Inf. Model. 2006; 46: 24-31.
52 Views | 50 Downloads
How to Cite
Darshana Gohate, and Parul Mehta. “2D and 3D QSAR Analysis of Imidazole Derivatives As Heme Oxygenase Inhibitor ”. Current Research in Pharmaceutical Sciences, Vol. 10, no. 2, Aug. 2020, pp. 19-29, doi:10.24092/CRPS.2020.100202.